title: New drugs on the horizon.
abstract: The agents covered in this article are useful in a wide range of illnesses, including infections, cancers, cardiovascular and gastrointestinal diseases, and others. One of the major forces driving the development of new drugs is the use of biotechnology. Biotechnology encompasses the techniques of recombinant DNA and monoclonal antibody technologies to produce protein drugs that have not been previously available in sufficiently pure form or in adequate quantities. As new drugs are developed, the authors hope that intensified efforts will be geared towards the development of unique drugs that offer important therapeutic gains.
authors.affiliation: Saint John's University College of Pharmacy and Allied Health Professions, Jamaica, New York.
authors.forename: G M
authors.initials: GM
authors.lastname: el-Chaar
authors.forename: M H
authors.initials: MH
authors.lastname: Schwenk
authors.forename: J
authors.initials: J
authors.lastname: Bardini
authors.forename: G
authors.initials: G
authors.lastname: Caliendo
authors.forename: C
authors.initials: C
authors.lastname: Frank
authors.forename: L M
authors.initials: LM
authors.lastname: Profeta
authors.forename: K A
authors.initials: KA
authors.lastname: Talbot
authors.forename: H
authors.initials: H
authors.lastname: Cohen
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000636:Aminosalicylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D017245:Foscarnet; D006397:Hematinics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D017294:Ondansetron; D004364:Pharmaceutical Preparations; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000636:Aminosalicylic Acids; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000932:Antiemetics; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D002317:Cardiovascular Agents; D006397:Hematinics; D007093:Imidazoles; D004364:Pharmaceutical Preparations; D012702:Serotonin Antagonists; D017245:Foscarnet; D017294:Ondansetron; C068069:nebacumab; D015242:Ofloxacin; D010746:Phosphonoacetic Acid; C032587:olsalazine